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Clostridium difficile is the leading cause of nosocomial antibiotic-associated diarrhea, and recent outbreaks
of strains with increased virulence underscore the importance of identifying novel approaches to treat and
prevent relapse of Clostridium difficile-associated diarrhea (CDAD). CDAD pathology is induced by two exo-
toxins, toxin A and toxin B, which have been shown to be cytotoxic and, in the case of toxin A, enterotoxic. In
this report we describe fully human monoclonal antibodies (HuMAbs) that neutralize these toxins and prevent
disease in hamsters. Transgenic mice carrying human immunoglobulin genes were used to isolate HuMAbs
that neutralize the cytotoxic effects of either toxin A or toxin B in cell-based in vitro neutralization assays.
Three anti-toxin A HuMAbs (3H2, CDA1, and 1B11) could all inhibit the enterotoxicity of toxin A in mouse
intestinal loops and the in vivo toxicity in a systemic mouse model. Four anti-toxin B HuMAbs (MDX-1388,
103-174, 1G10, and 2A11) could neutralize cytotoxicity in vitro, although systemic toxicity in the mouse could
not be neutralized. Anti-toxin A HuMAb CDA1 and anti-toxin B HuMAb MDX-1388 were tested in the
well-established hamster model of C. difficile disease. CDA1 alone resulted in a statistically significant reduc-
tion of mortality in hamsters; however, the combination treatment offered enhanced protection. Compared to
controls, combination therapy reduced mortality from 100% to 45% (P < 0.0001) in the primary disease
hamster model and from 78% to 32% (P < 0.0001) in the less stringent relapse model.
Clostridium difficile is a gram-positive spore-forming bacillus
and is the leading cause of nosocomial antibiotic-associated
diarrhea (4, 21). This disease is induced by the disruption of
the colonic flora through the administration of antibiotics such
as clindamycin, ampicillin, or cephalosporins (1). This pertur-
bation in the colonic microenvironment along with exposure to
C. difficile spores leads to colonization. Approximately one-
third of all patients that become colonized develop C. difficile-
associated diarrhea (CDAD) (28), and it has been estimated
that CDAD affects more than 300,000 patients per year in the
United States (15, 28, 31). Some studies have speculated that
CDAD increases the length of hospital stay by as much as 2
weeks for the average patient (30). Current treatment consists
of the discontinuation of the offending antibiotic as well as the
administration of metronidazole or vancomycin. This treat-
ment is typically successful, but approximately 10 to 20% of all
CDAD patients relapse when antibiotic therapy is halted (9).
Recent outbreaks of C. difficile strains with increased virulence
or antibiotic resistance have led to treatment failures, more-
frequent relapses, and increased mortality rates (8, 26, 27, 29).
In addition, the widespread use of vancomycin is commonly
restricted to prevent the emergence of vancomycin-resistant
enterococci.
C. difficile disease is mediated by two exotoxins, toxin A and
toxin B (2, 3, 5, 34, 35). Both are high-molecular-mass proteins
(280 to 310 kDa) that possess multiple functional domains.
The N-terminal domains of both toxins contain glucosyltrans-
ferase activity that modifies Rho-like GTPases (14, 16, 17).
This modification leads to cytoskeletal dysregulation in the
toxified cells and the disruption of colonic epithelial tight junc-
tions. The central domain is predicted to be involved in mem-
brane transport given the presence of hydrophobic regions and
caveolin binding sites (39). The C-terminal third of the toxins
contains repeating subunits believed to interact with carbohy-
drate receptors expressed on the target cell surface (38). The
interaction of toxin A with carbohydrates also induces the
hemagglutination of rabbit erythrocytes (6) and provides a
model for the study of toxin A receptor binding. Both toxins
are cytotoxic, with toxin B being 1,000 times more potent than
toxin A when tested in in vitro cytotoxicity assays, and both are
lethal when injected intravenously or intraperitoneally (i.p.)
into a mouse. Toxin A is also a potent enterotoxin, as demon-
strated by the induction of fluid accumulation in the mouse
ligated intestinal loop diarrhea model (12).
For humans, a variety of studies have suggested the impor-
tance of antibody in affecting disease outcome. Case series of
passive administration of intravenous immune globulin con-
taining anti-toxin A and B antibodies suggested the resolution
of symptoms for patients with CDAD (24, 32, 40). Immuniza-
tion of long-term relapsing humans with a combination toxoid
A-toxoid B vaccine has also been pursued to prevent additional
relapses (33). Finally, in a prospective controlled blinded
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study, serum anti-toxin A immunoglobulin G (IgG) concentra-
tions were shown to significantly correlate with protection from
CDAD (23). A second study also demonstrated that early
development of serum anti-toxin A antibody following pri-
mary disease was significantly correlated with protection
from relapse (22). These data support the role of antibody in
mitigating both primary disease and relapse associated with
C. difficile.
Studies with animal models have been conducted that dem-
onstrate the importance of the immune response in mitigating
CDAD. Hamsters, when challenged with C. difficile spores
following antibiotic treatment, develop fatal diarrhea and co-
litis, and the hamster model has been employed for the study
of CDAD. Immunization of hamsters with toxin A and toxin B
in combination, either actively or passively, has been shown to
prevent CDAD. The titers of serum antibodies to toxin A and
toxin B achieved following immunization correlated with levels
of protection from mortality induced by C. difficile (10, 13, 18,
19, 25, 36). Orogastric administration of chicken IgY directed
against toxin A could protect hamsters from CDAD (20). In
other animals, such as gnotobiotic mice, passive administration
of monoclonal antibody to toxin A could prevent disease (7).
These human and animal studies, taken together, demonstrate
the relevance of toxin-reactive antibodies in disease outcomes.
Here we describe the characterization of a panel of neutral-
izing, fully human monoclonal antibodies (HuMAbs) directed
against either toxin A or toxin B. Based on initial in vitro and
in vivo analysis, HuMAb CDA1 (against toxin A) and MDX-
1388 (against toxin B) were selected for further study in two
separate models of disease in hamsters. CDA1 alone could
protect hamsters from mortality, but significantly enhanced
protection was observed when the antibodies were adminis-
tered as a combination therapy.
MATERIALS AND METHODS
Cells and cell culture. IMR-90 and P3X-AG8.653 cells were obtained from the
ATCC. IMR-90 cells were cultured in minimal essential media supplemented
with 10% fetal calf serum (FCS) and 1% penicillin-streptomycin (P/S). P3X-
AG8.653 cells were cultured in RPMI supplemented with 10% FCS, 4 mM
glutamine, 1 mM pyruvate, 5 mM HEPES, 1% P/S, 55 M 2-mercaptoethanol.
Hybridomas were cultured in Dulbecco’s modified Eagle Medium (DMEM)
containing 10% FCS, nonessential amino acids, 1 oxaloacetate-pyruvate-insu-
lin (Sigma), 4 mM glutamine, 1 hypoxanthine-aminopterin-thymidine (Cell-
gro), 1 P/S, 1 hybridoma cloning factor (Bioveris), 2-mercaptoethanol
(GIBCO), and 10% NCTC-109 (GIBCO). All cells were propagated at 37°C in
air supplemented with 5% CO2.
Mouse immunization and splenic fusions. HuMAb mice (Medarex Inc.,
Bloomsbury, New Jersey) are transgenic for human immunoglobulin genes;
mouse heavy chain and kappa light chain immunoglobulin genes are inactivated.
HuMAb mice were injected weekly with 10 g of antigen using RIBI (Corixa) as
the adjuvant for 6 to 12 weeks. When toxin A or toxin B (both from Techlab) was
used as the antigen, toxin was inactivated prior to injection by the UDP-dialde-
hyde method described elsewhere (11). Enzyme-linked immunosorbent assay
(ELISA) was employed to measure serum responses to antigen, and animals
were sacrificed when serum responses reached a plateau. Hybridomas were
generated by the standard polyethylene glycol method with P3X63-AG8.653
mouse myeloma cells used as the fusion partner.
Identification of antigen-reactive hybridomas. Culture supernatants of hybrid-
omas and immunized mouse serum were assessed for antigen binding using
ELISA. Ninety-six-well microtiter plates were coated with 2 g/ml either of toxin
A or of toxin B in phosphate-buffered saline (PBS) overnight at 4°C. Two
hundred microliters of culture supernatant at various dilutions was added to the
wells and incubated at 22°C for 2 h. Antibody binding was detected using
anti-human IgG-alkaline phosphatase conjugate (1:5,000; Jackson Immuno-
Research), and plates were analyzed using a Molecular Devices Emax plate
reader (405 nm) with Softmax software.
Antibody purification. Hybridoma cell cultures were expanded, and superna-
tant was harvested by centrifugation. Small-scale culture supernatants were in-
cubated with protein A- or protein G-Sepharose (Amersham) for 2 h at room
temperature while rocking. Beads were removed by column filtration, and anti-
body was eluted with 100 mM glycine, pH 2.8. The eluate was dialyzed against
PBS and concentrated using an Amicon Centriprep YM-30 concentrator as
described by the manufacturer. Purified antibody was filter sterilized and protein
concentration quantitated by spectrophotometry. For large-scale antibody puri-
fication, HiTrap (Amersham) protein A column chromatography was employed
and purified antibody was concentrated as described above.
Toxin neutralization assays. IMR-90 cells were seeded at 1 105 cells per well
in a 96-well microtiter plate and incubated for 12 h at 37°C with 5% CO2. Toxin
A (6 ng/ml) or toxin B (20 pg/ml) was incubated with various concentrations of
antibody for 1 h, added to the cell culture, and incubated for 18 h at 37°C.
Cytopathic effect was determined microscopically and scored as 0 (0% rounded
cells), 1 (25% rounded cells), 2 (50% rounded cells), 3 (75% rounded cells), or
4 (100% rounded cells).
Hemagglutination assay. Various concentrations of purified antibody were
incubated with toxin A (0.5 g) for 1 h at 4°C in a 96-well microtiter plate in a
total volume of 25 l of PBS. Rabbit erythrocytes (R-RBC; Colorado Serum Co.)
were washed with PBS and resuspended to 2% (vol/vol) in PBS. Twenty-five
microliters of 2% R-RBC was added to the wells of the 96-well plate and
incubated for 4 h at 4°C. Plates were scored visually, with hemagglutination
presenting as diffuse red cells in the well and the absence of hemagglutination
observed as all red blood cells settled in the well.
Synthesis and purification of recombinant proteins. C. difficile strain VPI
10463 was grown for 20 h in thioglycolate medium (BBL), and 1 ml of bacterial
suspension was centrifuged at 5,000 rpm for 5 min. The bacterial pellet was
solubilized and DNA purified using a DNeasy kit (QIAGEN) as described by the
manufacturer. Purified DNA was resuspended in 500 l for subsequent use in
PCR. The DNA sequences for C. difficile (strain VPI 10463) toxin A and toxin B
were obtained from NCBI (#X92982). Primers were designed to amplify four
various fragments from each of the toxin A and toxin B genes (Table 1). 5
oligonucleotides were modified to contain a BamHI restriction site, and the 3
oligonucleotides were modified with a 5 SacI restriction site. PCR was per-
formed in a reaction mixture containing 1 l genomic DNA, 20 M deoxynucleo-
side triphosphates, 20 pmol of each oligonucleotide, 1 cloned Pfu reaction
buffer (Stratagene), and 1 U Turbo Pfu (Stratagene). Forty cycles of thermocy-
cling (95°C for 15 s, 55°C for 30 s, and 68°C for 1 to 10 min) were performed, and
the PCR products were resolved on 1% agarose gels. PCR products were puri-
fied using a gel extraction kit (QIAGEN) and subsequently digested with BamHI
and SacI. Digested PCR products were ligated into pET32 (Novagen), which
contains an upstream gene encoding bacterial thioredoxin and a downstream
sequence encoding the His6 epitope tag. All cloned genes were sequenced to
confirm that no errors had accumulated during the PCR process.
BL21Star Escherichia coli cells (Invitrogen) were transformed with pET32
toxin fragment vector and grown overnight at 37°C in 20 ml of Luria broth
containing 100 g/ml ampicillin (LB-ampicillin). The culture was diluted 1:20
into 200 ml of LB-ampicillin and grown for 2.5 h at 37°C, and 1 mM IPTG
(isopropyl--D-thiogalactopyranoside) was added. For toxin A fragments, the
culture was shifted to 22°C and incubated for 2 h. For toxin B fragments, cultures
were incubated for 2 h at 37°C. Bacteria were harvested by centrifugation and
frozen at 80°C for 30 min. Pellets were resuspended in 10 ml of PBS supple-
mented with 350 mM NaCl and 1 mg/ml lysozyme. The suspension was incubated
for 30 min on ice followed by 10 min at 22°C while rocking. CHAPS {3-[(3-
cholamidopropyl)-dimethylammonio]-1-propanesulfonate}, DNase, and RNase
were added to give final concentrations of 1%, 10 g/ml, and 10 g/ml, respec-
tively. The mixture was rocked at 22°C for 30 min and the insoluble material
removed by centrifugation at 5,000  g for 15 min. Cleared lysate was incubated
with Ni-nitrilotriacetic acid agarose for 2 h at 22°C, and resin was removed by
column filtration. Proteins were eluted with 250 mM imidazole, dialyzed against
PBS, and concentrated with an Amicon Centriprep YM-30 concentrator as
described by the manufacturer.
Sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis and West-
ern blotting. Various concentrations of purified toxin fragments were mixed with
2 reducing Laemmli sample buffer and incubated at 37°C for 45 min. Samples
were resolved using 10% or 12% Novex gels (Invitrogen) for 1.5 h at 200 V. Gels
were transferred to Immobilon P (Millipore) as described by the manufacturer,
and Western blot analysis was performed. Proteins were detected using either
purified HuMAbs (1 g/ml) or anti-His6 antibody (0.1 g/ml; Invitrogen) fol-
lowed by an anti-human or anti-mouse IgG-horseradish peroxidase conjugate
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(1:5,000; Jackson ImmunoResearch). Membranes were incubated with ECL re-
agent (Amersham) for 1 min and exposed to XOMAT-AR film for various
periods of time.
Neutralization of mouse toxicity. Swiss Webster mice were injected intraperi-
toneally with 100 to 250 g of HuMAbs and rested for 24 h. One hundred
nanograms of either toxin A or toxin B was injected intraperitoneally, and the
mice were observed for up to 72 h. The Fisher exact test was used for all
statistical analyses.
Inhibition of intestinal fluid accumulation. CD1 mice were injected intraperi-
toneally with various concentrations of purified HuMAbs directed against toxin
A or PBS (untreated positive control). Animals were rested for 16 h, during
which time food was withheld. Animals were anesthetized with 100 mg keta-
mine/kg of body weight and 10 mg xylazine/kg administered intraperitoneally. A
1-cm incision was made in the abdomen of the mouse, and the ileum was
isolated. A vascularized section of ileum approximately 3 cm in length was doubly
ligated as to separate it from the general intestinal tract. Toxin A (0.45 g; 150
l) was carefully injected into the lumen of the ligated section of ileum. The
ileum was returned into the abdomen of the mouse and the incision closed with
surgical staples. The animal was allowed to recover after the surgery was com-
pleted and was sacrificed 4 h later. The ligated ileum was removed from the
animal with surgical scissors, and its weight and length were determined.
C. difficile spore preparation. C. difficile strain B1 (gift of Dale Gerding) was
grown for 24 h in thioglycolate medium and subsequently streaked on blood agar
plates. A total of 40 blood agar plates were incubated anaerobically for 7 days,
and the bacterial lawn was scraped into DMEM. Spores were centrifuged at
500  g for 30 min at 4°C and resuspended in 100 ml of DMEM. Spore suspen-
sions were frozen and stored at 80°C. To assess the spore number in the bank,
one vial of spores was thawed and plated in limiting dilution on cycloserine-
cefoxitin-fructose agar and incubated anaerobically for 3 days at 37°C. CFU were
counted, and the number of spores/ml was calculated.
Hamster primary challenge model. Syrian golden hamsters (70 to 80 g) were
given four total doses of HuMAb (MDX1388 and CDA1) or 1 ml anti-toxin B
goat serum intraperitoneally for 4 days beginning 3 days prior to the adminis-
tration of C. difficile spores. Clindamycin (10 mg/kg) was administered intraperi-
toneally 24 h prior to C. difficile spore challenge, and the hamsters were chal-
lenged with 140 B1 spores orogastrically using a standard small animal feeding
needle. Animals were observed for morbidity and mortality, and the experiment
terminated when all remaining hamsters were considered healthy. The Fisher
exact test was used for all statistical analyses.
Hamster relapse model. Syrian golden hamsters (70 to 80 g) were given 10
mg/kg clindamycin intraperitoneally and 24 h later challenged with 140,000 C.
difficile B1 spores orogastrically. At the time of spore administration, vancomycin
treatment (10 mg/kg/day orogastrically) was begun and continued daily for a total
of 3 days. Beginning 48 h following spore challenge, HuMAbs or 1 ml goat serum
was injected intraperitoneally twice per day for a total of 5 days. Animals were
observed for morbidity and mortality, and the experiment terminated when all
remaining hamsters were considered healthy. The Fisher exact test was used for
all statistical analyses.
RESULTS
Isolation of human monoclonal antibodies directed against
Clostridium difficile toxins A and B. To generate HuMAbs
reactive with Clostridium difficile toxin A, transgenic mice con-
taining active human immunoglobulin genes (HuMAb mice;
Medarex Inc.) were immunized with toxoid A (inactivated
toxin A) for 6 to 12 weeks. Serum titers directed against toxin
A were measured by antigen-specific ELISA, and splenic fu-
sions were performed on mice that produced a robust anti-
toxin A immune response. Screening yielded 16 toxin A-reac-
tive hybridomas from a total of seven mice. Supernatants from
all 16 hybridomas contained human  heavy chains as well as
human  light chains. Fifteen of the reactive supernatants
contained human IgG1, whereas one clone (clone 3H2) pro-
duced human IgG3.
To generate HuMAbs directed against toxin B, two immu-
nogens were used. A recombinant fragment of toxin B that
includes the C-terminal 590 amino acids of toxin B (toxin B
fragment 4) was cloned and expressed. This domain contains
repeated sequences and is believed to be involved in the bind-
ing of toxin B to cellular receptor. HuMAb mice were immu-
nized with either whole C. difficile toxoid B (inactivated toxin
B) or the recombinant toxin B fragment 4 for 6 to 12 weeks.
Splenic fusions were performed on mice with a potent immune
response to toxin B as measured by ELISA. From animals
immunized with toxoid B, a total of 17 toxin B-reactive hybrid-
omas were identified from four distinct animals. Fusion of
toxin B fragment 4-immunized animals (eight HuMAb mice)
yielded 55 hybridomas reactive to toxin B as measured by
TABLE 1. Oligonucleotides used for the construction of recombinant toxin fragments
Toxin Fragment
Oligonucleotidea
bp amplified Amino acids
Forward Reverse
A 1 GGTTGCTGGATCCATGTCTTTAATA
TCTAAAGAAGAGTTAATAAAACT
CGCATATAGC
CCATGCTGAGCTCGCTTCATCTTTAC
CATGTCCAATAAAGGTTACTTTTA
CTTTTTCC
1–1977 1–659
A 2 GGTTGCTGGATCCTTCAACACAAG
CGAATTTGCTAGATTAAGTGTAG
ATTCAC
CCATGCTGAGCTCGCTGAATCAAGT
AATCTAGTTCCGTCATTTTCCAAT
GATC
1978–3768 660–1256
A 3 GGTTGCTGGATCCATAAGAGATTT
ATACCCAGGTAAATTTTACTGGA
GATTCTATGC
CCATGCTGAGCTCGCATTATTTATAT
TGATTAATCCTTTAACTAATTTACT
ATCTTCATCATAG
3769–5556 1257–1852
A 4 GGTTGCTGGATCCTCATTATTCTAT
TTTGATCCTATAGAATTTAACTTA
GTAACTGGATGG
CCATGCTGAGCTCGCGCCATATATC
CCAGGGGCTTTTACTCCATCAAC
5557–8130 1853–2710
B 1 GCTTGCTGGATCCAGTTTAGTTAAT
AGAAAACAGTTAGAAAAAATGG
CCATGCTGAGCTCGCTTCATAACTA
ATTTTATCTCCTTGTAACTG
1–1638 1–546
B 2 GCTTGCTGGATCCGCAGCATGTAA
CTTATTTGCAAAG
CCATGCTGAGCTCGCTATATCATCA
GTTACAGTATGACCTGAAC
1639–3553 547–1184
B 3 GCTTGCTGGATCCGATCACTTCTTT
TCAGCACCATC
CCATGCTGAGCTCGCCAAAGTCTTA
TCTTTAAAAACATTAACGAATC
3553–5328 1185–1776
B 4 GGTTGCTGGATCCGCAAATAAGCT
ATCTTTTAACTTTAGTGATAAAC
AAGATGTACC
CCATGCTGAGCTCGCTTCACTAATC
ACTAATTGAGCTGTATCAGGATCA
AAATAATAC
5329–7098 1777–2366
a Underlining denotes the introduction of restriction sites to facilitate molecular cloning.
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ELISA. All 72 distinct toxin B-reactive hybridomas secreted
human IgG1 with  light chains.
Identification of HuMAb antibodies that neutralize toxin A
and toxin B in vitro. The in vitro cytotoxicity induced by both
toxin A and toxin B was measured in the IMR-90 cytotoxicity
assay. In this assay, monolayers of IMR-90 cells are exposed to
toxin for 24 h, and dramatic morphological changes can easily
be observed. Cultures are scored on a scale of 0 to 4, in which
0 indicates no toxic effect and 4 signifies that 100% of the cells
have lost their typical morphology and are rounded. Notably,
toxin A is much less potent than toxin B in this assay and
requires approximately 1,000-fold-higher concentrations to in-
duce a similar cytotoxicity level.
Cell cultures for the 16 toxin A-reactive HuMAbs were
scaled to larger volumes, and antibody was purified by protein
A/G chromatography. All purified HuMAbs were tested for
the ability to neutralize toxin activity in vitro. IMR-90 cells
were plated and incubated for 24 h with toxin A (6 ng/ml) in
the presence of various concentrations of purified antitoxin
HuMAb antibodies. Three purified anti-toxin A HuMAbs,
clones CDA1, 1B11, and 3H2, showed neutralizing activity
against toxin A, and the results of a representative experiment
are shown in Fig. 1A. A total of five comparative experiments
were performed, and the hierarchy of toxin A neutralization
potency was found to be 1B11 	 3H2 	 CDA1.
Given the large numbers of hybridomas reactive to toxin B
in ELISA (a total of 72), supernatants were first screened for
the presence of neutralization activity in the IMR-90 assay.
Four supernatants contained detectable activity in this assay
(clones MDX1388, 1G10, 103-174, and 2A11; data not shown),
and antibodies for each were purified by protein A chroma-
tography. Clones MDX1388 and 1G10 were derived from an-
imals immunized with toxin B fragment 4, and 103-174 and
2A11 arose from animals immunized with toxoid B. All four
purified HuMAbs were incubated at various concentrations
with 20 pg/ml of toxin B and applied to IMR-90 cells to assess
the neutralization of toxin B-mediated cytotoxicity. Cultures
were scored as described above, and the results of a represen-
tative experiment are shown in Fig. 1B. MDX1388 and 103-174
showed potent toxin B-neutralizing activity, with half-maximal
activity levels of 0.1 nM and 1 nM, respectively (average of four
comparative experiments). 1G10 possessed moderate neutral-
ization capacity, and 2A11 was a very weak neutralizing
HuMAb. Overall, these data demonstrate that three of our
toxin A-reactive HuMAbs and four of our toxin B-reactive
HuMAbs can neutralize their respective toxins in the in vitro
cytotoxicity assay.
CDA1, but not 3H2 or 1B11, inhibits hemagglutination in-
duced by toxin A. The direct interaction of toxin A with its
cellular receptor is difficult to study. Staining hamster colonic
epithelium with toxin A is laborious (13). Toxin A does, how-
ever, hemagglutinate rabbit erythrocytes. The repeating sub-
units of the toxin A receptor-binding domain are thought to
interact with specific carbohydrate residues of the rabbit eryth-
rocytes, leading to cross-linking and subsequent hemagglutina-
tion. We used hemagglutination as a surrogate for studying the
interaction of toxin A with its cellular receptor. Various con-
centrations of toxin A (from 2 to 0.001 g/well) and PBS as the
negative control were mixed with rabbit erythrocytes, and the
mixtures were seeded to microtiter plates and incubated at 4°C
for 4 h. Plates were scored for toxin A-induced hemagglutina-
tion as demonstrated by a diffuse distribution of erythrocytes in
the well (as opposed to a typical button of erythrocytes in the
negative control). Concentrations of 0.25 g/well could com-
pletely induce hemagglutination, and 0.5 g/well was selected
as the standard concentration to test for hemagglutination
inhibition. Toxin A (0.5 g/well) was incubated with various
concentrations (12.5 to 0.006 g/well) of either CDA1, 3H2, or
1B11 HuMAb and subsequently mixed with rabbit erythrocytes
and incubated for 4 h at 4°C. HuMAb CDA1 could inhibit
hemagglutination at concentrations as low as 0.4 g/well,
whereas neither 1B11 nor 3H2 could block hemagglutination,
even at the highest concentrations tested. These data suggest
that CDA1, but not 1B11 or 3H2, can disrupt the interaction
between toxin A and its cellular receptor.
HuMAbs to toxin A but not toxin B can neutralize in vivo
mouse toxicity. Toxins A and B, when administered i.p. to a
mouse, induce lethality in a significant number of animals in
less than 72 h. The mechanism of death is presumably related
to the cytotoxic effects of the toxins. Although this model does
FIG. 1. In vitro neutralization of cytotoxicity. (A) C. difficile toxin A (6 ng/well) was mixed with either HuMAb CDA1, 3H2, or 1B11 at various
antibody concentrations from 100 to 0.001 nM. IMR-90 cells were plated at 1  105 cells/well in a 96-well microtiter plate, and toxin A-antibody
mixtures were applied to the cells. IMR-90 cells with a toxin A-antibody mixture applied were incubated for 24 h and scored for cytopathic effect
(CPE) visually on a scale of 0 to 4, where 0 represents no observed toxicity and 4 indicates that 100% of the monolayer was effected by toxin A.
(B) The experiment was performed as described for panel A, with the exception that C. difficile toxin B (20 pg/well) was mixed with either HuMAb
2A11, MDX1388, 1G10, or 103-174 at various antibody concentrations from 1,000 to 0.0001 nM prior to being applied to IMR-90 cells.
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not mimic enteric disease, it is a measure of the ability to
neutralize circulating toxin in an animal. Swiss Webster mice
were injected intraperitoneally with 1B11, CDA1, or 3H2 (100
to 250 g/dose) 24 h prior to the administration of toxin A.
Toxin A (100 ng) was injected i.p., and animals were observed
for 48 to 72 h for mortality. Results of multiple experiments are
shown in Fig. 2A. Animals treated with 100 to 250 g of an
irrelevant HuMAb had a survival rate of 23% (24/105). The
survival rates for 1B11, CDA1, and 3H2 were 24% (12/50),
67% (60/90), and 74% (52/70), respectively. 1B11 showed no
reduction in mortality compared to controls; however, both
3H2 and CDA1 provided significant protection from mortality
compared to the irrelevant HuMAb.
In vivo mouse toxicity assays were also done using toxin B to
test the neutralizing activity of the anti-toxin B HuMAbs. Swiss
Webster mice were injected i.p. with 100 to 250 g of either
MDX1388, 1G10, 2A11, 103-174, irrelevant HuMAb, or goat
anti-toxin B 24 h prior to toxin B administration. Toxin B (100
ng) was injected i.p., the mice were observed for 72 h, and
survival rates were determined. Six percent (3/50) of mice
treated with an irrelevant HuMAb survived the challenge
within 72 h. Survival rates for animals treated with MDX1388,
2A11, 1G10, and 103-174 were 8% (4/50), 10% (2/20), 10%
(2/20), and 20% (4/20), respectively (data not shown). Animals
treated systemically with goat anti-toxin B had a survival rate
of 98% (49/50). These data demonstrate that none of the
anti-toxin B HuMAbs could individually protect mice from
lethality associated with toxin B. Polyclonal goat serum, how-
ever, showed potent neutralization of toxin B in this model.
Neutralizing HuMAbs directed against toxin A can prevent
fluid accumulation in mouse intestinal loops. Toxin A is a
potent enterotoxin and has been shown to induce fluid accu-
mulation in the mouse intestinal tract in a model utilizing an
isolated section of mouse ileum (37). Briefly, surgery was per-
formed on the mouse, and the ileum, proximal to the cecum,
was doubly ligated, creating a section of ileum isolated from
the general intestinal tract. Toxin A (0.45 g) was then injected
into the ligated region, and the animal was allowed to recover
from surgery. Approximately 4 h after the completion of sur-
gery, mice were euthanized, and the ligated sections of ilea
were removed. The excised ileum was weighed and measured
to calculate a weight-to-length ratio. Ileum that accumulated
fluid had a measurable increase in weight, causing an increase
in the weight-to-length ratio.
Mice were injected i.p. with 500 g to 2 mg of either 1B11 (6
mice), CDA1 (19 mice), 3H2 (17 mice), or PBS (19 mice
[untreated controls]) approximately 24 h prior to surgery. Sur-
gery was performed, toxin A was administered, and animals
were euthanized after 4 h. Weight-to-length ratios of the ex-
cised ileal loops were calculated; the average ratios are shown
in Fig. 2B. Mice that did not receive antibody treatment had a
mean weight-to-length ratio of 11.2 mg/mm (range 
 4.8 to 22
mg/mm). Weight-to-length ratios for 1B11-, CDA1-, and 3H2-
treated mice were calculated to be 5.4 mg/mm (range 
 2.9 to
7.2 mg/mm), 7.0 mg/mm (range 
 3.3 to 12.4), and 7.6 mg/mm
(range 
 1.7 to 11.3), respectively. As control for fluid accu-
mulation due to injection trauma, PBS was injected into the
ligated ileal loop in place of toxin A. Weight-to-length ratios
for the PBS (no toxin) control ilea had a mean of 4.5 mg/mm
(range 
 2.7 to 6.1). These data demonstrate that all three
HuMAbs can neutralize enterotoxicity in the mouse ileum
relative to what is seen for untreated controls.
Domain mapping of toxin A- and toxin B-neutralizing
HuMAbs. The toxin A protein contains several different func-
tional domains. The N-terminal 25% of the protein contains
the enzymatic domain (Rho glucosylation), the central domain
contains a putative transmembrane domain, and the C-termi-
nal 30% contains the repeating subunits thought to be required
for receptor binding (Fig. 3A). We generated four recombi-
nant fragments of toxin A containing the N- and C-terminal
domains as well as two fragments spanning the central region
of the protein (Fig. 3A). The recombinant proteins were ex-
pressed and resolved by SDS-polyacrylamide gel electrophore-
sis and detected by Western blotting using mouse anti-His6
(epitope tag), 3H2, CDA1, or 1B11 as detection reagents (data
not shown). All four recombinant proteins were detected by
anti-His6 antibody. HuMAb 3H2 bound only to toxin A frag-
ment 2. HuMAb CDA1 recognized toxin A fragment 4 (recep-
FIG. 2. Neutralization of in vivo toxicity in mice. (A) Mice were treated with 100 to 250 g either of an irrelevant HuMAb or of 1B11, CDA1,
or 3H2 24 h prior to intraperitoneal administration of 100 ng of toxin A. Animals were observed for up to 72 h, and the percentages of surviving
animals were plotted. The number of animals tested in each group is shown above the respective column in the bar graph, with P values indicated
(the Fisher exact test). NS, not significant. (B) Mice were injected i.p. with 500 g to 2 mg of 1B11, CDA1, or 3H2 24 h prior to ileal loop surgery.
As an untreated positive control, mice were injected i.p. with PBS rather than antibody (no antibody). As a negative control for fluid accumulation
due to surgery, PBS was injected into the ligated loop in place of toxin A (no toxin). The number of animals in each group is shown above the
respective column in the bar graph. Toxin A (0.45 g) was injected into ligated ileal loops of treated animals, and loops were excised 4 hours later.
Weight-to-length ratios were calculated and plotted.
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tor-binding domain) but not fragments 1, 2, or 3. HuMAb 1B11
interacted with toxin A fragment 1 (enzymatic domain) but not
fragments 2, 3, or 4. These data demonstrate that the three
neutralizing HuMAbs recognize three distinct epitopes (Fig.
3A) within toxin A and suggest that multiple mechanisms for
neutralization are possible. The recognition by Western blot-
ting further suggests that the epitopes recognized by all three
HuMAbs are not irreversibly sensitive to denaturation with
SDS and may be linear in nature.
To domain map our toxin B-reactive HuMAbs, we focused
on the most well-defined domains of toxin B. The domain
structure of toxin B is similar to that of toxin A, with fragment
1 representing the enzymatic domain and fragment 4 repre-
senting the ligand-binding domain (Fig. 3B). MDX1388 and
1G10 were isolated from mice immunized with recombinant
toxin B fragment 4, and not surprisingly, these HuMAbs are
shown by Western blotting to recognize toxin B fragment 4
(data not shown). However, 103-174 and 2A11 were isolated
from animals immunized with whole toxoid B and thus could
presumably recognize any domain of toxin B. When assayed
with Western blotting for the ability to bind to the two recom-
binant fragments of toxin B, 103-174 was found to bind
strongly to fragment 1, and 2A11 interacted with fragment 4.
None of these antibodies recognized toxin B fragments 2 or 3
in Western blot analysis (data not shown). Thus, three of our
in vitro neutralizing HuMAbs recognize the receptor-binding
domain, whereas one interacts with the enzymatic domain of
toxin B (Fig. 3B). All of these HuMAbs recognize denatured
antigen, as shown by recognition by Western blotting, and thus
may recognize linear epitopes.
Antitoxin HuMAbs protect hamsters from mortality associ-
ated with C. difficile disease. Given that the anti-toxin A
HuMAb CDA1 interacts with the receptor-binding domain
and demonstrates activity in all in vitro and in vivo assays, we
selected this monoclonal antibody as our lead anti-toxin A
candidate for use in hamsters. Also, MDX1388 was selected as
the lead candidate anti-toxin B HuMAb, given its potent neu-
tralization activity in in vitro studies and its recognition of the
toxin B receptor-binding domain. Hybridoma cultures of the
two lead HuMAbs were scaled to larger volumes in both spin-
ners and bioreactors for large-scale production of HuMAb.
Antibodies were purified from culture supernatants using pro-
tein A affinity chromatography and quantitated by spectropho-
tometry.
The hamster model of C. difficile disease is a well-established
model for the study of toxin-induced antibiotic-associated
diarrhea. The most extensively studied model of C. difficile
infection in hamsters is the primary challenge model. Briefly,
hamsters were treated with clindamycin 24 h prior to the ad-
ministration of C. difficile spores to disrupt the normal colonic
flora in the hamster. C. difficile spores (140 spores, B1 strain)
were administered orogastrically, and the hamsters were ob-
served. Typically, 100% of hamsters succumb to disease be-
tween 36 and 72 h after spore administration. Prior to mortal-
ity, symptoms of disease include diarrhea, weight loss, loss of
muscle control, and difficulty in breathing. In general, the
symptoms are much more severe than those seen in humans,
but the hamster model responds to therapeutic maneuvers
used in clinical disease and is therefore widely used in the study
of C. difficile disease.
For the study of the antitoxin monoclonal antibody combi-
nation therapy, hamsters were treated intraperitoneally with
CDA1 (50 mg/kg/day), MDX1388 (10 to 50 mg/kg/day), or a
combination of the two for a total of 4 days (72, 48, 24, and 0 h
prior to the administration of C. difficile spores). Hamsters
were injected intraperitoneally with clindamycin 24 h prior to
the orogastric delivery of 140 C. difficile strain B1 spores. Ham-
sters were observed for mortality daily until all hamsters had
either succumbed to disease or become free of disease symp-
toms.
We conducted a total of six experiments to test the abilities
of our HuMAb antibodies directed against toxins A and B to
protect hamsters from primary challenge with C. difficile, and
the results are summarized in Fig. 4. CDA1 alone offered
significant early protection compared to no treatment (day 2,
23/42 [surviving hamsters/total hamsters]; P  0.0001), al-
though this protection waned at later time points (day 	5,
2/42). However, combination therapy with CDA1 and
MDX1388 resulted in increased protection at day 2 (61/65; P
0.0001) as well as significant protection throughout the study
FIG. 3. Domain recognition of toxin A- and toxin B-reactive HuMAbs. (A) Schematic representation of recombinant fragments cloned and
expressed in E. coli, with amino acid numbers listed above and below the figure. Specific antibodies are listed below the recognized domain.
(B) Schematic of recombinant toxin B fragments that were cloned and expressed in E. coli, with amino acid numbers listed above and below the
figure. Specific antibodies are listed below the recognized domain.
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period (36/65; P 0.0001). Finally, MDX1388 administered as
a single agent did not offer protection at any time point with
this model.
We modified the primary disease hamster model to simulate
the effects of CDA1 and MDX1388 to control relapse. Van-
comycin protects hamsters from C. difficile disease, as it does in
humans. When vancomycin treatment is discontinued, ham-
sters relapse with severe disease, but the attack rate varies.
Hamsters were given a single dose of clindamycin followed by
the orogastric administration of C. difficile strain B1 spores
(140,000 CFU) 1 day later. Vancomycin treatment began on
the day of spore challenge and continued daily for two subse-
quent days (three total doses of 10 mg/kg/day).
We conducted multiple experiments to assess the thera-
peutic benefit of MDX1388 and CDA1 (60 mg/kg/day and 20
mg/kg/day, respectively, days 2 to 6 following spore chal-
lenge) in preventing mortality in the relapse model of in-
fection in the hamster. In the summary data analysis (Fig. 5),
CDA1 administered in addition to vancomycin prevented
relapse at day 6 after challenge in 56% (48/86) of hamsters
compared to 38% (31/82) of those who received vancomycin
alone (P 
 0.02); by day 10 after challenge, the rates for the
groups were similar. However, combination treatment with
CDA1 and MDX1388 offered significant protection at both
early and late time points, with 68% survival at day 6 (15/22;
P  0.015) and 68% at day 10 (15/22; P  0.0001), compared
to what was seen for vancomycin-treated controls, which
showed 38% and 22% survival at these time points. It is
noteworthy that no protection was seen for animals treated
with MDX1388 alone at either time point, with only 27%
survival (4/15) being observed.
DISCUSSION
A growing body of evidence suggests that antibodies di-
rected against toxins A and B may provide additional benefit to
the standard treatment regimens for CDAD. The current
treatment for nosocomial antibiotic-associated diarrhea in-
duced by C. difficile is the discontinuation of the offending
antibiotic followed by the administration of vancomycin or
metronidazole. This treatment is generally effective, yet re-
lapse of symptoms occurs in a significant number of patients
(up to 20%). The development of strains with increased viru-
lence (thought to be mediated by excess toxin production) or
with antibiotic resistance as well as the need to restrict vanco-
mycin use to prevent the emergence of vancomycin-resistant
enterococci underscores the need for alternative therapeutics.
Antibody therapy that directly neutralizes toxins and interferes
with the mechanism of C. difficile pathogenesis may also be
expected to lead to more-rapid and more-durable therapeutic
effects.
Here we describe the identification and characterization of a
panel of HuMAbs directed against both toxins A and B of C.
difficile. Toxin A-directed HuMAbs CDA1, 3H2, and 1B11
could neutralize in vitro cytotoxicity and prevent fluid accumu-
lation in mouse intestinal loops. However, only CDA1 and 3H2
could neutralize systemic toxicity in the mouse, and only CDA1
had the capacity to prevent toxin A-induced hemagglutination
of rabbit erythrocytes. Epitope mapping demonstrated that
these three HuMAbs recognized very diverse regions of the
toxin, with CDA1 recognizing the C-terminal third of toxin A,
3H2 interacting with the central domain, and 1B11 binding to
the N terminus. We speculate that 1B11 neutralizes the enzy-
matic activity of toxin A and that CDA1 prevents the binding
of toxin A to a cognate receptor found on the surface of the
target cell. The function of 3H2 is difficult to surmise, but it
FIG. 4. Protection of hamsters with HuMAbs in the primary chal-
lenge model. Hamsters were treated with CDA1 (50 mg/kg/day) alone
or in combination with MDX1388 (10 to 50 mg/kg/day) for 4 days
beginning 3 days prior to spore administration. Clindamycin (10 mg/
kg) was injected intraperitoneally 24 h prior to spore challenge. Spores
were delivered orogastrically, and animals were observed for up to 11
days. A total of six experiments were performed, and a summary of all
hamster primary challenge experiments using percent survival at either
2 or 	5 days after challenge is shown. The fractions above the bar
graphs represent the numbers of surviving animals (numerators) and
the total numbers of animals (denominators), with P values indicated
(the Fisher exact test). NS, not significant.
FIG. 5. Protection of hamsters with HuMAbs in the relapse model.
Clindamycin (10 mg/kg) was injected intraperitoneally 24 h prior to
spore challenge. Spores were administered orogastrically, at which
time vancomycin treatment (10 mg/kg/day) was initiated and continued
for a subsequent 2 days. Hamsters were treated with CDA1 (60 mg/
kg/day) in combination with MDX1388 (20 mg/kg/day) for 4 days
beginning 2 days following spore administration. Animals were ob-
served for mortality until day 10. A summary of all hamster relapse
model experiments using percent survival at either 6 or 10 days fol-
lowing challenge was graphed. The fractions above the bar graphs
represent the numbers of surviving animals (numerators) and the total
numbers of animals (denominators), with P values indicated (the
Fisher exact test). NS, not significant.
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may prevent the internalization of toxin A by binding to the
transmembrane domain or caveolin binding sites. Since CDA1
possessed the broadest range of neutralization activity in these
various assays and is presumed to act extracellularly to block
toxin A interaction with cells (in contrast to the need to remain
associated with toxin to prevent intracellular glucosyltrans-
ferase activity), we chose CDA1 as our lead candidate anti-
toxin A HuMAb.
Fewer methods exist for assessing the neutralization of toxin
B. The IMR-90 cytotoxicity assay with toxin B is the lone in
vitro procedure that can be performed. Our four anti-toxin B
HuMAbs, MDX1388, 1G10, 103-174, and 2A11, all had the
capacity to neutralize toxin B in this assay, albeit at very dif-
ferent concentrations. MDX1388 had the most potent neutral-
izing activity, with a half-maximal activity level of 0.1 nM. It
was demonstrated that three of the HuMAbs interacted with
the receptor-binding domain of toxin B (2A11, 1G10, and
MDX1388), whereas one, 103-174, bound to the enzymatic
domain, suggesting that these two groups neutralize different
functional activities of toxin B.
Interestingly, none of the four toxin B-specific HuMAbs
could protect mice from a lethal challenge with toxin B. In in
vitro assays using IMR-90 fibroblasts, toxin B is much more
cytotoxic than toxin A (1,000 times) and this challenge (100
ng) in mice may be too severe for our monoclonal antibodies to
provide protection. Unfortunately, this level of toxin B is re-
quired to induce consistent lethality in the model. It is impor-
tant to note, however, that goat anti-toxin B polyclonal anti-
body could protect mice from toxin B challenge. The potency
of the goat serum against toxin B in the in vitro cytotoxicity
assay is much greater than that of MDX1388, and careful
comparisons based on in vitro neutralization data could not be
made in the mouse model. Perhaps the optimal neutralization
of toxin B in the in vivo mouse intoxification model depends on
the presence of more than one epitope specificity. To address
this point, we used a cocktail of all four toxin B-reactive HuMAbs
in the mouse model yet still saw no protection from mortality
(data not shown). MDX1388 was chosen as our lead candidate
anti-toxin B HuMAb due to its potent in vitro neutralizing
activity and its presumed capacity to block the interaction of
toxin B with cellular receptors.
Because the hamster provides a well-characterized model of
C. difficile infection, we chose this animal model to test our
lead antitoxin HuMAbs in both the standard primary disease
and relapse models. Hamsters treated with antibiotics to dis-
rupt colonic flora and then exposed to C. difficile spores suc-
cumb to diarrheal disease in less than 48 h. Treatment of
hamsters with a combination of HuMAbs CDA1 and
MDX1388 offered protection from mortality both in the pri-
mary disease model and in the relapse model of infection. In
the primary disease model, which consistently demonstrates
100% mortality, the combination treatment protected 55% of
challenged hamsters from death associated with C. difficile. In
the relapse model, with various mortality rates, significant pro-
tection was also observed. These data demonstrate that the
combination treatment of CDA1 and MDX1388 provides ben-
efit for untreated hamsters as well as for hamsters receiving
vancomycin as a therapeutic. Since these HuMAbs demon-
strated protection in such a severe disease model, we speculate
that a combination HuMAb cocktail of CDA1 and MDX1388
could also be a useful therapeutic either standing alone or
in combination with antibiotics for the treatment of CDAD
in humans.
Studies have suggested that C. difficile disease outcome in
humans is correlated with circulating titers of toxin A-directed
antibody. Once colonized with C. difficile, individuals with high
levels of serum IgG against toxin A developed disease at a rate
lower than that seen for controls with low anti-toxin A serum
titers. Also, anti-toxin A antibody titers correlated with pro-
tection from relapse. In our hamster primary disease and re-
lapse models, CDA1 treatment alone delayed the onset of
mortality and disease symptoms but did not protect from mor-
tality by the culmination of the experiments. Given that the
outcome of CDAD in humans in much less severe than that in
the hamster, it is also possible that CDA1 treatment, in the
absence of antibody to toxin B, may still provide some benefit
to humans with CDAD.
. We noted that protection of hamsters from C. difficile
disease required a very high dose of CDA1 (50 mg/kg/day for
4 days). However, circulating titers of CDA1 were measured in
some hamsters treated with the above-described regimen, and
surprisingly, serum titers were very similar to those that have
been seen for human volunteers receiving a single dose of 10
mg/kg (data not shown). Given the administration of such a
high dose, it is unclear why the serum titers achieved in the
hamsters are so low. In fact, we have found that approximately
10% of all hamsters tested have no measurable titer of
HuMAb in the circulation even after a total of 200 mg of
antibody is administered intraperitoneally (for both CDA1 and
other HuMAbs tested) (unpublished data). Lower-than-antic-
ipated titers in the hamster sera could be the result of the
inefficient transport of human antibodies from the peritoneum
into the bloodstream. It is also possible that some hamsters
generate an immune response to the human antibody and clear
it quickly from the circulation. Given the measured levels of
circulating protective titers in the hamster sera, we believe a
single dose of 10 mg/kg of CDA1 may be beneficial in the
treatment of CDAD in humans and achieve serum levels con-
ferring both therapeutic activity and protection from relapse.
Based on the data presented herein, CDA1 and MDX1388
have been chosen for testing in clinical trials for treatment of
CDAD or prevention of relapses. Phase I clinical trials of
CDA1 in healthy subjects have been completed, and phase II
clinical trials are currently being conducted. Phase I trials with
the combination of CDA1 and MDX1388 have been initiated,
with a phase II trial of combination therapy planned to begin
soon. Results of phase II trials will determine if single or
combination therapy will be studied in a phase III efficacy trial.
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